Efficacy of erlotinib and celecoxib for patients with advanced non-small cell lung cancer: A retrospective study

This study evaluated the efficacy and toxicity of erlotinib and celecoxib (EC) for treating Chinese patients with advanced non-small cell lung cancer (ANSCLC) and epidermal growth factor receptor (EGFR) wild type. Totally, 75 subjects with ANSCLC and EGFR wild type were included. They all underwent...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Yi-Hua, Li, Wei-Hong, Bai, Yan, Ni, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6417627/
https://www.ncbi.nlm.nih.gov/pubmed/30855490
http://dx.doi.org/10.1097/MD.0000000000014785

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6417627/
https://www.ncbi.nlm.nih.gov/pubmed/30855490
http://dx.doi.org/10.1097/MD.0000000000014785

Ejemplares similares